Caribou Biosciences, Inc. (CRBU)
NasdaqGS · USD · Healthcare · Biotechnology
$0.4895 (-0.55%) as of
Key statistics
- Market cap
- 52.48M
- Forward P/E
- -0.55
- EPS (TTM)
- -1.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.4430 – 3.5350
- Beta
- 2.31
- Revenue (TTM)
- 10.04M
- Profit margin
- 0.00%
- Analyst target
- $5.75
- Volume
- 40.94k
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Berkeley, CA, United States
- Employees
- 97
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.